IPP Bureau
Borrena approval strengthens Pfizer position in China NSCLC market: GlobalData
By IPP Bureau - May 25, 2022
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
Cipla scored highest among pharma companies in CRISIL’s Sustainability Rating 2022
By IPP Bureau - May 25, 2022
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
Lonza partners with Israel Biotech Fund to support biologics and small molecules development
By IPP Bureau - May 25, 2022
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
European Commission approves Keytruda plus chemotherapy as neoadjuvant treatment for breast cancer
By IPP Bureau - May 25, 2022
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
ENPICOM launches versatile display data analysis solution to accelerate antibody selection
By IPP Bureau - May 25, 2022
The new IGX-Track App adds seamless analysis of antibody panning campaigns to the IGX Platform
Fitelo unveils new branding after Pre-Series A fund-raise
By IPP Bureau - May 25, 2022
Each member of Fitelo's team of experts gives highly personalized attention and recommendations to their clients ensuring they reach their fitness goals holis
Piramal Pharma Solutions upgrades Pithampur site
By IPP Bureau - May 25, 2022
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
Thyrocare launches its Regional Processing Lab in Nagpur on World Thyroid Day
By IPP Bureau - May 25, 2022
The new advanced regional processing lab will serve Nagpur city and the Vidarbha region
Sputnik V demonstrates strong protection against Omicron variant
By IPP Bureau - May 25, 2022
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Pfizer offers patent-protected medicines on not-for-profit to 45 low income countries
By IPP Bureau - May 25, 2022
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
Max Healthcare Institute Q4 FY2022 consolidated PAT slips QoQ to Rs. 123.73 Cr
By IPP Bureau - May 25, 2022
The company has posted net profit of Rs.605.05 crores for the Financial Year ended March 31, 2022
Johnson & Johnson and Momenta Pharmaceuticals file lawsuit against NATCO Pharma
By IPP Bureau - May 25, 2022
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
IPCA Laboratories posts Rs. 130.23 crores consolidated profit in Q4FY22
By IPP Bureau - May 25, 2022
The company has posted net profit of Rs.884.08 crores for the Financial Year ended March 31, 2022.
Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol
By IPP Bureau - May 24, 2022
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Indica Labs achieves CE-IVD certification for AI-based prostate cancer detection and Gleason grading tool
By IPP Bureau - May 24, 2022
The HALO Prostate AI algorithm deployed in HALO AP from Indica Labs
